edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Onxeo is focused on cancer indications specialising in epigenetics and DNA break repair inhibition. Beleodaq, a HDAC inhibitor, is approved for PTCL in the US and partnered with Spectrum Pharmaceuticals. AsiDNA, a novel DNA break repair inhibitor from Onxeo’s platON platform, is expected to enter Phase I in 2018.
Get access to the very latest content matched to your personal investment style.